NASDAQ:CDMO Avid Bioservices (CDMO) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free CDMO Stock Alerts $6.41 +0.02 (+0.31%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$6.31▼$6.6650-Day Range$6.09▼$8.7952-Week Range$4.07▼$19.97Volume511,100 shsAverage Volume883,213 shsMarket Capitalization$405.37 millionP/E RatioN/ADividend YieldN/APrice Target$14.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Avid Bioservices alerts: Email Address Avid Bioservices MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside122.3% Upside$14.25 Price TargetShort InterestHealthy15.99% of Shares Sold ShortDividend StrengthN/ASustainability-0.96Upright™ Environmental ScoreNews Sentiment1.16Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.89 out of 5 starsMedical Sector199th out of 909 stocksPharmaceutical Preparations Industry78th out of 418 stocks 3.4 Analyst's Opinion Consensus RatingAvid Bioservices has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAvid Bioservices has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted15.99% of the outstanding shares of Avid Bioservices have been sold short.Short Interest Ratio / Days to CoverAvid Bioservices has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Avid Bioservices has recently decreased by 6.73%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvid Bioservices does not currently pay a dividend.Dividend GrowthAvid Bioservices does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAvid Bioservices has received a 68.99% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biopharmaceuticals", "Clinical research services", and "Process engineering services for the pharmaceutical industry" products. See details.Environmental SustainabilityThe Environmental Impact score for Avid Bioservices is -0.96. Previous Next 2.9 News and Social Media Coverage News SentimentAvid Bioservices has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Avid Bioservices this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for CDMO on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Avid Bioservices to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avid Bioservices insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.39% of the stock of Avid Bioservices is held by insiders.Percentage Held by Institutions97.16% of the stock of Avid Bioservices is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Avid Bioservices is -37.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avid Bioservices is -37.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvid Bioservices has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Avid Bioservices Stock (NASDAQ:CDMO)Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.Read More CDMO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDMO Stock News HeadlinesApril 21, 2024 | seekingalpha.comLaughing Water Capital - Avid Bioservices: A Few Years Away From Large, Relatively Sticky FCFApril 18, 2024 | americanbankingnews.comAvid Bioservices, Inc. (NASDAQ:CDMO) Short Interest UpdateApril 23, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMOApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMOMarch 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMOMarch 20, 2024 | globenewswire.comAvid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-QMarch 20, 2024 | finance.yahoo.comCDMO Dec 2024 10.000 callApril 23, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...March 16, 2024 | ca.finance.yahoo.comCDMO Apr 2024 15.000 callMarch 16, 2024 | ca.finance.yahoo.comCDMO Dec 2024 2.500 callMarch 14, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of InvestorsMarch 14, 2024 | businesswire.comAvid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsMarch 13, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of InvestorsMarch 13, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of InvestorsMarch 7, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Alimera (ALIM), Avid Bioservices (CDMO)March 7, 2024 | investorplace.comWhy Is Avid Bioservices (CDMO) Stock Down 30% Today?March 7, 2024 | marketwatch.comAvid Bioservices Shares Slide After Pricing Private Placement of Convertible NotesMarch 7, 2024 | msn.comAvid Bio slumps after Q3 results and convertible debt offeringMarch 6, 2024 | globenewswire.comAvid Bioservices Announces Pricing of Private Placement of Convertible NotesMarch 6, 2024 | globenewswire.comAvid Bioservices Announces Proposed Private Placement of Convertible NotesMarch 6, 2024 | globenewswire.comAvid Bioservices Announces Proposed Private Placement of Convertible NotesMarch 6, 2024 | globenewswire.comAvid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024March 6, 2024 | globenewswire.comAvid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024February 18, 2024 | finance.yahoo.comCDMO Mar 2024 7.500 putFebruary 14, 2024 | msn.comContract research firms gain after Q4 resultsJanuary 30, 2024 | uk.finance.yahoo.comGlobal Veterinary CRO and CDMO Market Report 2023: Growth Surge in Asia-Pacific & Innovative Product TrendsSee More Headlines Receive CDMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/21/2023Today4/22/2024Next Earnings (Estimated)4/22/2024Fiscal Year End4/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CDMO CUSIPN/A CIK704562 Webwww.avidbio.com Phone(714) 508-6100Fax714-838-5817Employees365Year FoundedN/APrice Target and Rating Average Stock Price Target$14.25 High Stock Price Target$20.00 Low Stock Price Target$7.00 Potential Upside/Downside+122.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$560,000.00 Net Margins-8.12% Pretax Margin-8.22% Return on Equity-5.18% Return on Assets-2.16% Debt Debt-to-Equity Ratio0.81 Current Ratio1.35 Quick Ratio0.85 Sales & Book Value Annual Sales$149.27 million Price / Sales2.72 Cash Flow$0.15 per share Price / Cash Flow41.43 Book Value$3.03 per share Price / Book2.12Miscellaneous Outstanding Shares63,240,000Free Float61,728,000Market Cap$405.37 million OptionableOptionable Beta1.63 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Nicholas Stewart Green B.Sc. (Age 59)MBA, President, CEO & Director Comp: $1.35MMr. Daniel R. Hart (Age 51)Chief Financial Officer Comp: $719.75kMr. Richard Richieri (Age 59)Chief Operations Officer Comp: $561.68kMr. Mark R. Ziebell J.D. (Age 60)VP, General Counsel & Corporate Secretary Comp: $647.1kMr. Matthew Kwietniak (Age 55)Chief Commercial Officer Comp: $553.59kMs. Oksana LukashVice President of PeopleMore ExecutivesKey CompetitorsFulcrum TherapeuticsNASDAQ:FULCAnnexonNASDAQ:ANNXMersana TherapeuticsNASDAQ:MRSNLarimar TherapeuticsNASDAQ:LRMRNeurogeneNASDAQ:NGNEView All CompetitorsInsiders & InstitutionsMather Group LLC.Bought 7,143 shares on 4/9/2024Ownership: 0.011%CWM LLCSold 2,653 shares on 4/5/2024Ownership: 0.006%PNC Financial Services Group Inc.Sold 16,306 shares on 3/22/2024Ownership: 0.006%Wellington Management Group LLPBought 315,600 shares on 3/5/2024Ownership: 2.338%Stephens Inc. ARBought 97,037 shares on 2/13/2024Ownership: 0.401%View All Insider TransactionsView All Institutional Transactions CDMO Stock Analysis - Frequently Asked Questions Should I buy or sell Avid Bioservices stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CDMO shares. View CDMO analyst ratings or view top-rated stocks. What is Avid Bioservices' stock price target for 2024? 4 Wall Street analysts have issued 1-year price objectives for Avid Bioservices' stock. Their CDMO share price targets range from $7.00 to $20.00. On average, they expect the company's stock price to reach $14.25 in the next twelve months. This suggests a possible upside of 122.3% from the stock's current price. View analysts price targets for CDMO or view top-rated stocks among Wall Street analysts. How have CDMO shares performed in 2024? Avid Bioservices' stock was trading at $6.50 on January 1st, 2024. Since then, CDMO stock has decreased by 1.4% and is now trading at $6.41. View the best growth stocks for 2024 here. Are investors shorting Avid Bioservices? Avid Bioservices saw a decline in short interest in March. As of March 31st, there was short interest totaling 10,110,000 shares, a decline of 6.7% from the March 15th total of 10,840,000 shares. Based on an average trading volume of 1,330,000 shares, the days-to-cover ratio is currently 7.6 days. View Avid Bioservices' Short Interest. How were Avid Bioservices' earnings last quarter? Avid Bioservices, Inc. (NASDAQ:CDMO) released its quarterly earnings results on Wednesday, June, 21st. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.07. The biopharmaceutical company earned $39.80 million during the quarter, compared to the consensus estimate of $39 million. Avid Bioservices had a negative net margin of 8.12% and a negative trailing twelve-month return on equity of 5.18%. During the same quarter in the prior year, the firm earned $0.04 earnings per share. What ETF holds Avid Bioservices' stock? Franklin Genomic Advancements ETF holds 7,643 shares of CDMO stock, representing 0.56% of its portfolio. When did Avid Bioservices' stock split? Avid Bioservices shares reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What guidance has Avid Bioservices issued on next quarter's earnings? Avid Bioservices updated its third quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $33.8 million-$33.8 million, compared to the consensus revenue estimate of $34.2 million. What is Roger Lias' approval rating as Avid Bioservices' CEO? 5 employees have rated Avid Bioservices Chief Executive Officer Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among the company's employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 63.0% of employees surveyed would recommend working at Avid Bioservices to a friend. What other stocks do shareholders of Avid Bioservices own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE). Who are Avid Bioservices' major shareholders? Avid Bioservices' stock is owned by a variety of institutional and retail investors. Top institutional investors include Mather Group LLC. (0.01%) and CWM LLC (0.01%). Insiders that own company stock include Daniel R Hart, Gregory Sargen, Joseph Carleone, Mark R Ziebell, Matthew R Kwietniak, Nicholas Stewart Green, Richard A Richieri and Richard B Hancock. View institutional ownership trends. How do I buy shares of Avid Bioservices? Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDMO) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avid Bioservices, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
